

1 **Title: Estimated incidence rate of specific cardiovascular**
2 **and respiratory hospitalizations attributable to**
3 **Respiratory Syncytial Virus among adults in Germany**
4 **between 2015 and 2019**

5

6 **Author Details:**

7 Caihua Liang¹, Aleksandra Polkowska-Kramek², Caroline Lade³, Lea Johanna
8 Bayer³, Robin Bruyndonckx², Bennet Huebbe³, Worku Biyadgie Ewnetu², Pimnara
9 Peerawaranun², Maribel Casas², Thao Mai Phuong Tran², Gordon Brestrich³,
10 Christof von Eiff³, Bradford D. Gessner¹, Elizabeth Begier⁴, Gernot Rohde⁵

11

12 **Affiliations:**

13 ¹ Pfizer Inc-New York (USA)

14 ² P95 Epidemiology & Pharmacovigilance, Leuven, Belgium

15 ³ Pfizer Pharma GmbH - Berlin (Germany)

16 ⁴ Pfizer Inc - Dublin (Ireland)

17 ⁵ Goethe University Frankfurt, University Hospital, Medical Clinic I, Department of
18 Respiratory Medicine, Frankfurt/Main, Germany

19

20 **Corresponding author:**

21 Caihua Liang

22 Email: caihua.liang@pfizer.com

23 Address: 66 Hudson Blvd E, New York, NY 10001

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Abstract**

25 **Introduction:** Respiratory syncytial virus (RSV) can cause severe outcomes among
26 adults. However, RSV incidence in adults is frequently underestimated due to non-
27 specific symptomatology, limited standard-of-care testing, and lower test sensitivity
28 compared to infants. We conducted a retrospective observational study to estimate
29 RSV-attributable incidence of hospitalizations among adults in Germany between 2015
30 and 2019.

31 **Methods:** Information on hospitalizations and the number of people at risk of
32 hospitalization (denominator) was gathered from a Statutory Health Insurance (SHI)
33 database. A quasi-Poisson regression model accounting for periodic and aperiodic time
34 trends and virus activity was fitted to estimate the RSV-attributable incidence rate
35 (IR) of four specific cardiovascular hospitalizations (arrhythmia, ischemic heart
36 diseases, chronic heart failure exacerbations, cerebrovascular diseases) and four
37 specific respiratory hospitalizations (influenza/pneumonia, bronchitis/bronchiolitis,
38 chronic lower respiratory tract diseases, upper respiratory tract diseases).

39 **Results:** RSV-attributable IRs of hospitalizations were generally increasing with age.
40 Among cardiovascular hospitalizations in adults aged ≥ 60 years, arrhythmia and
41 ischemic heart diseases accounted for the highest incidence of RSV-attributable
42 events, followed by chronic heart failure exacerbation, with annual IR ranges of 157–
43 260, 133–214, and 105–169 per 100,000 person-years, respectively. The most
44 frequent RSV-attributable respiratory hospitalizations in adults aged ≥ 60 years were
45 for chronic lower respiratory tract diseases and bronchitis/bronchiolitis, with annual IR
46 ranges of 103–168 and 77–122 per 100,000 person-years, respectively.

47 **Conclusion:** RSV causes a considerable burden of respiratory and cardiovascular
48 hospitalizations in adults in Germany, similar to other respiratory viruses (e.g.,

49 influenza and SARS-CoV-2). This highlights the need to implement effective
50 prevention strategies, especially for older adults.

51 **Keywords:**

52 RSV, cardiorespiratory, hospitalization, Germany, quasi-Poisson, time-series modeling

53 **Key Summary Points:**

- 54 • Respiratory syncytial virus (RSV) disease burden in adults is significant yet
55 often remains unrecognized due to unspecific symptoms, lack of routine testing
56 and lower test sensitivity compared to infants.
- 57 • Using a quasi-Poisson regression time-series model, we estimated the age-
58 stratified RSV-attributable incidence of specific cardiovascular and respiratory
59 hospitalizations in Germany between 2015 and 2019.
- 60 • Estimated cardiorespiratory RSV hospitalization rates increased with age and
61 were significantly higher in older adults.
- 62 • Arrhythmia, ischemic heart diseases, and chronic lower respiratory tract
63 disease exacerbation were the most frequent causes of RSV-attributable
64 cardiovascular and respiratory hospitalizations.
- 65 • RSV causes a considerable burden of respiratory and cardiovascular
66 hospitalizations among adults in Germany, and effective RSV vaccines could
67 improve public health outcomes, especially for older adults.

68 **Introduction**

69 Respiratory syncytial virus (RSV) usually causes mild respiratory infections but
70 may also lead to severe lower respiratory tract diseases such as chronic
71 obstructive pulmonary disease exacerbation and pneumonia (1). RSV affects
72 people of any age, but the risk of severe infections and hospitalizations is highest
73 among infants, adults aged 60 years and above, and those with comorbidities (1-
74 4).

75 The incidence rate (IR) and clinical burden of RSV disease in adults are
76 challenging to measure due to symptoms resembling influenza and other co-
77 circulating respiratory viruses (5). Limited standard-of-care RSV testing among
78 adults, single specimen collection (i.e., use of nasopharyngeal/nasal swab only)
79 and reduced sensitivity of diagnostic testing compared to children (6-9) contribute
80 to the underestimation of the RSV burden. Additionally, inadequate RSV diagnostic
81 capacity in many healthcare facilities (5, 8, 10, 11) and low awareness of RSV,
82 particularly for patients with cardiopulmonary manifestations, hinder measuring
83 the actual RSV burden (12). Further, even when RSV is diagnosed via laboratory
84 testing, other non-specific acute respiratory infection codes may be used for
85 administrative diagnoses (13).

86 RSV-associated exacerbation of underlying cardiopulmonary diseases may
87 contribute to a large and unrecognized burden of RSV disease (12). Several
88 studies demonstrated that RSV can cause exacerbation of asthma and chronic
89 obstructive pulmonary disease (COPD) (14-17) (18). Growing evidence indicates
90 that RSV is associated with cardiovascular diseases such as acute myocardial
91 infarction, stroke, arrhythmia, exacerbation of congestive heart failure (CHF), and

92 coronary artery disease (CAD) (12, 19-26). Nonetheless, data on RSV-attributable
93 cardiovascular hospitalizations in adults is limited.

94 Due to severe under-ascertainment of RSV cases in adults, the recent burden of
95 RSV estimates is more commonly based on mathematical models. Those models
96 relate the temporal variability of the community activity of RSV (indicated by, e.g.,
97 week-to-week RSV disease case counts) to the variability in disease outcomes that
98 may be caused or triggered by an RSV infection (e.g., COPD exacerbation
99 hospitalizations and cardiovascular hospitalizations). Among those outcomes, the
100 model estimates the portion expected to be RSV-attributable (10, 27-29).

101 In Germany, data on the RSV burden from prospective observational incidence
102 studies are unavailable (30), but a recent model-based study showed considerable
103 RSV morbidity and mortality between 2015 and 2019 (31). The estimated RSV-
104 attributable hospitalization IRs increased with age, with high rates observed
105 among people 60 years and above (respiratory diseases: 236–363 per 100,000
106 person-years; cardiovascular diseases: 558–885 per 100,000 person-years; and
107 cardiorespiratory diseases: 584–912 per 100,000 person-years) (31). However,
108 detailed data on RSV-attributable hospitalizations in more specific respiratory and
109 cardiovascular subgroups are still lacking.

110 Providing such estimates would help to better understand the burden imposed by
111 RSV and guide the formulation of vaccine policies. Lately, RSV vaccines have been
112 licensed to prevent lower respiratory tract disease caused by RSV in adults 60
113 years and above. Two RSV vaccines [GSK's RSV Arexvy vaccine (32) and Pfizer's
114 RSV Abrysvo vaccine (33)] for adults aged 60 years and above have been
115 available in Germany since 2023. In 2024, market authorization received a third
116 RSV vaccine [Moderna's mRESVIA vaccine] (34).

117 We conducted a model-based study to estimate RSV-attributable hospitalizations
118 of four respiratory (influenza/pneumonia, bronchitis/bronchiolitis, chronic lower
119 respiratory tract diseases, upper respiratory tract diseases) and four
120 cardiovascular (chronic heart failure exacerbation, ischemic heart diseases,
121 arrhythmia, cerebrovascular diseases) conditions in Germany.

122 **Methods**

123 **Study design**

124 We conducted an observational retrospective study to estimate the IRs of specific
125 respiratory and cardiovascular hospitalizations attributable to RSV among adults in
126 Germany using a quasi-Poisson regression model.

127 **Data sources**

128 Data on hospitalizations was sourced from the Deutsche Analysedatenbank für
129 Evaluation und Versorgungsforschung (DADB) database from Gesundheitsforen
130 Leipzig (GFL). This database contains Statutory Health Insurance (SHI) data of
131 approximately 3.5 million insured individuals. Participants included in the study
132 were adults aged 18 years and above. The age and sex structure of the DADB
133 database is similar to that of the German population, with adjustment factors to
134 account for a slightly younger population in DADB available (35). The study
135 period, from 2015 to 2019, was selected to avoid any distortions in RSV
136 epidemiology due to the COVID-19 pandemic (36).

137 The study included eight disease outcomes, coded according to the German
138 Modification (GM) of the International Classification of Diseases, 10th revision
139 (ICD-10-GM). These include four specific respiratory outcomes [influenza/
140 pneumonia (J10-J18), bronchitis/bronchiolitis (J20-J22), chronic lower respiratory
141 tract diseases (J40-J47), upper respiratory tract diseases (J00-J06, J30-J39)], and

142 four specific cardiovascular outcomes [chronic heart failure (I42-I43, I50, I51.7),
143 ischemic heart diseases (I20-I25), arrhythmias (I44-I49), and cerebrovascular
144 diseases (I60-I68)]. To compare the difference between the number of observed
145 (reported in the database) and attributable (model-based) RSV events, we
146 obtained RSV-specific hospitalizations (B97.4, J21.0, J12.1, J20.5) stratified by
147 age group.

148 Hospitalization was defined as an overnight stay in a hospital commencing from
149 the admission date. If subsequent hospitalizations for the same outcome occurred
150 within 30 days from discharge, these were collapsed with the initial hospitalization
151 to avoid overcounting cases due to readmission.

152 Individuals were categorized into four age groups: 18-44, 45-59, 60-74, and 75
153 years and above. The 60-year and above cut-off was selected because RSV
154 vaccines are approved for this age group in Germany. For anonymization
155 purposes, data were suppressed if fewer than 5 cases were reported in the age
156 group and outcome stratum.

157 The indicator for RSV circulation was defined as the weekly number of RSV-related
158 hospitalizations in children under two years of age (ICD-10-GM codes: B97.4,
159 J21.0, J12.1, J20.5, J21.9). As in other studies (10, 26, 28, 37), we selected RSV
160 circulation in children due to the higher frequency of testing and hospitalization in
161 this age group and the higher sensitivity of diagnostic tests compared to adults (8,
162 38). As most bronchiolitis cases in young children are caused by RSV, we also
163 included J21.9 (acute bronchiolitis, unspecified) (39-41) as a proxy for RSV
164 circulation. The indicator for influenza circulation was defined as the weekly
165 number of influenza-specific hospitalizations (ICD-10-GM codes: J09, J10, J11) in
166 adults aged 60 years and above (37).

167 **Statistical analysis**

168 Upon observation of seasonality, age-group-stratified weekly aggregated data
169 were modeled using a quasi-Poisson regression model. The model was constructed
170 according to the previously published protocol (42). The model accounts for
171 baseline periodic and aperiodic time trends, viral activity (RSV and influenza) and
172 potential overdispersion.

173 With these fitted models, we obtained the annual number of RSV-attributable
174 events and the proportion of RSV-attributable events for each outcome and age
175 group as described in the protocol (42).

176 Yearly IRs of RSV-attributable events, expressed in the number of events per
177 100,000 person-years, were obtained by dividing the annual model-based number
178 of RSV-attributable events by the population at risk. This age-specific population
179 at risk of the event was obtained from the DADB database. No effort was made to
180 limit the denominator to persons at risk for the given condition (e.g., estimate
181 COPD exacerbation incidence only among persons with COPD diagnosis). Because
182 the DADB database, from which our estimates were obtained, has a slightly
183 younger population compared to the overall German population covered by SHI,
184 the yearly RSV-attributable events were multiplied with age-specific correction
185 factors based on data provided by GFL to scale the IRs to a nationally
186 representative level.

187 Confidence intervals were obtained via residual bootstrapping. All data
188 management and statistical analyses were conducted using R software (version
189 4.0.4).

190

191

192 **Ethical considerations**

193 This study used aggregated and anonymized data, therefore not requiring
194 approval from Institutional Review Boards or Ethical Committees or informed
195 consent from patients. The study was conducted following legal and regulatory
196 requirements and research practices described in the Good Epidemiological
197 Practice guidelines issued by the International Epidemiological Association (43).

198

199 **Results**

200 **Observed hospitalizations**

201 Between 2015 and 2019, the diagnoses with the largest number of
202 hospitalizations were due to arrhythmia and ischemic heart diseases, responsible
203 for 266,463 and 259,052 hospitalizations, respectively. Among respiratory
204 hospitalizations, chronic lower respiratory tract diseases were responsible for
205 162,344 hospitalizations, with influenza/pneumonia (74,064 hospitalizations)
206 accounting for the most (Supplementary Table 1). The majority of hospitalizations,
207 amounting to 70% or more, involved individuals aged 60 years and above. The
208 exception to this trend was observed in upper respiratory tract diseases, where
209 most hospitalizations (74% or more) occurred in younger adults aged 18-59
210 years.

211 The reported number of RSV-specific hospitalizations based on ICD code
212 diagnoses alone throughout the study period was 24 cases across all age groups.
213 However, the total number of RSV-specific hospitalizations is unknown as, during
214 most weeks in which RSV-specific hospitalizations were reported, counts were
215 below five and hence suppressed for anonymity.

216

217 **Estimated RSV-attributable hospitalizations**

218 The estimated IR of RSV-attributable diseases showed year-to-year fluctuations,
219 with the highest incidence observed for most outcomes in 2017. Due to a lack of
220 adequate seasonal fluctuations, several outcomes were not modeled in the
221 youngest age group. For cerebrovascular diseases, only data for the age group 75
222 years and above were suitable for modeling (Table 1 and Table 2).

223 The estimated IR of RSV-attributable respiratory hospitalizations in the age group
224 60 years and above was highest for chronic lower respiratory tract diseases (range
225 across the study period: 103-168 hospitalizations per 100,000) and bronchitis/
226 bronchiolitis (77-122 hospitalizations per 100,000) (Table 1). The IRs of RSV-
227 attributable bronchitis/bronchiolitis hospitalizations for those aged 75 years and
228 above were approximately 11- to 12-fold and 32- to 43-fold higher than the rates
229 for adults aged 60-74 years and 45-59 years, respectively. Similarly, the rates of
230 chronic lower respiratory diseases were approximately 3- to 4-fold and 12- to 15-
231 fold higher in the oldest age group (≥ 75 years) compared to younger age groups
232 (60-74 and 45-59 years) (Table 1).

233 RSV-attributable proportions were comparable between age groups and
234 respiratory subgroups (range 1-5% in age groups 45-59 years and 60-74 years,
235 and 3-8% in ≥ 75 years) with the exception of bronchitis or bronchiolitis where the
236 RSV-attributable proportion was 1-10% for younger age groups and 17-25% for
237 adults 75 years and above (Table 1). For cardiovascular causes, arrhythmia (157-
238 260 per 100,000 person-years) and ischemic heart diseases (133-215 per
239 100,000 person-years), followed by chronic heart failure (105-169 per 100,000
240 person-years) showed the highest RSV-attributable IRs (Table 2) in adults aged
241 ≥ 60 years. The RSV-attributable IRs were notably higher in older age groups,
242 particularly among hospitalized individuals aged 75 years and above. The rates of

243 RSV-attributable arrhythmia and ischemic heart disease hospitalizations for those
244 aged 75 and above were both approximately 4-fold higher than the rates for
245 adults aged 60-74 years. Moreover, these rates were about 25-fold and 21-fold
246 higher, respectively, than for adults aged 45-59 years (Table 2). RSV-attributable
247 proportions were comparable between age groups and cardiovascular subgroups,
248 accounting for approximately 1% to 3% of all hospitalizations (Table 2).

249

250 **Discussion**

251 Our study complements the results of the first model-based study in Germany
252 (31) by providing estimates on specific types of cardiorespiratory hospitalizations
253 attributable to RSV. We found a high burden of cardiovascular hospitalizations
254 related to RSV, with RSV-attributable IRs for arrhythmia (157-260 per 100,000
255 person-years) and ischemic heart diseases (133-215 per 100,000 person-years)
256 being the two highest among all studied conditions in adults aged 60 years and
257 above. Among respiratory conditions, chronic lower respiratory tract diseases
258 (103-168 per 100,000 person-years) and bronchitis/bronchiolitis (77-122 per
259 100,000 person-years) had the highest RSV-attributable incidences in adults aged
260 60 years and over. As in other studies, we found that RSV-attributable IRs were
261 increasing with age, with a considerable surge observed in patients aged 60 years
262 and older. Our findings were considerably higher than those based on RSV-specific
263 ICD-10 codes alone, suggesting vast under-ascertainment of RSV cases in adults.
264 Substantially lower RSV hospitalization rates in adults aged >59 years (0.11-
265 11.36 per 100,000 person-years) were also reported in an observational study in
266 Germany, which was based on data on primary discharge diagnosis of RSV (J21.1,
267 J20.5, J21.0) (44).

268 Our study adds to the growing evidence of the association between RSV circulation
269 and cardiovascular events. We found that approximately 2% to 3% of
270 hospitalizations due to arrhythmia, ischemic heart diseases, and chronic heart
271 failure in people 60 years and above were attributed to RSV. In the oldest age
272 group (75 years and above), we also found an association – in line with another
273 study – between RSV and cerebrovascular diseases, with 1% to 2% of those
274 hospitalizations being attributable to RSV. For instance, in Spain, the RSV-
275 attributable proportion of ischemic heart diseases in adults aged 60 years and
276 above (3%) and cerebrovascular diseases in adults aged 80 years and above (2%)
277 were comparable to our results (26). Although the RSV-attributable proportions
278 were comparable, it resulted in higher IRs, most likely due to overall higher
279 observed hospitalizations due to cardiovascular causes in Germany. This might be
280 related to different coding practices or different prevalence of comorbidities in
281 those two populations.

282 Several mechanisms are considered to explain the relationship between RSV and
283 cardiovascular events. Part of those conditions may be related to the indirect
284 effect of inflammation due to acute respiratory infections. Inflammation may
285 increase the concentration of C-reactive protein, inflammatory cytokines and
286 clotting factors such as fibrinogen, leading to an increased risk of thrombotic
287 coronary occlusion (20, 45, 46). Additionally, it may cause endothelial dysfunction
288 and inhibit the function of vasodilating nitric oxide or prostaglandins, contributing
289 to arterial and venous thromboembolic disease (47). Development of pulmonary
290 hypertension may lead to secondary myocardial dysfunction, hypotension and
291 arrhythmia (24). RSV can also directly infect organs, as it was isolated from
292 myocardial tissue biopsies in patients with myocarditis (19, 24). Cardiovascular
293 diseases remain the leading cause of morbidity and mortality worldwide (48).

294 Thus, the potential impact of a vaccine preventing cardiovascular events, as
295 observed for the influenza vaccine (49, 50), might be substantial.

296 Our estimates for RSV-attributable hospitalizations due to bronchitis/ bronchiolitis
297 (77-122 per 100,000) and influenza/pneumonia diagnosis grouping (67-98 per
298 100,000) in adults aged 60 years and above align with the study conducted in
299 Spain (100-110 per 100,000 and 83-91 and, respectively) (26). The Spanish
300 study utilized the same generic protocol that we used for this study. In contrast,
301 when compared to another model-based study from the United Kingdom, IRs in
302 older age groups (65-74 and ≥ 75 years) were considerably higher in Germany
303 (10). The possible reason is using different methods (quasi-Poisson regression
304 modeling weekly counts vs linear regression modeling weekly outcome rates) and
305 a different RSV proxy definition (weekly hospitalizations due to RSV vs weekly RSV
306 counts from the surveillance system). We used RSV hospitalization data as a
307 proxy because hospitalization data is less affected by the testing practices than
308 the surveillance data, which will be mostly driven by influenza (data not shown).
309 Further, the UK study used primary diagnosis codes, which have been shown to
310 underestimate incidence in validation studies (51).

311 Among age groups 45-59 and 60-74 years, the highest RSV-attributable IR was
312 revealed for chronic lower respiratory tract diseases. Respiratory viruses, including
313 RSV, are known causes of exacerbation of COPD (16). In prospective cohort
314 studies, approximately 4% to 11% of COPD patients tested positive for RSV (52,
315 53). The prevalence of COPD is increasing globally, leading to enormous
316 healthcare costs and high mortality (54, 55). Exacerbation of COPD is associated
317 with an accelerated decline in lung function, progression of the disease and lower
318 quality of life (15). Thus, preventing COPD exacerbation should be a public health
319 priority, and vaccination of COPD patients should be prioritized, as suggested by

320 the recent recommendation from the US Centers for Disease Control and
321 Prevention (56).

322 Our study showed considerable under-ascertainment of RSV cases in adults in
323 Germany. Other studies also observed low testing activity and considerable
324 underestimation of the RSV burden in adults (8, 9, 26) when only RSV-specific
325 ICD codes are used. These findings highlight the need for systematic testing and
326 reporting, including patients presenting with cardiovascular manifestations or
327 exacerbation of underlying respiratory diseases.

328 The main strength of our study was the use of a large database of approximately
329 3.5 million insured persons, an extended study period of five years and the
330 inclusion of eight different medical conditions, allowing for a more sensitive
331 estimation of the RSV burden. In addition, our study was based on a generic
332 protocol (42) that permits robust comparisons between countries. The protocol
333 was developed based on an extensive prior literature review and experts' input.

334 We also acknowledge some study limitations. Our model included only RSV and
335 influenza as viral indicators, assuming those are the only pathogens related to the
336 outcome of interest. However, by inclusion of the periodic component and
337 overdispersion parameter, we indirectly accounted for other potentially relevant
338 pathogens. Second, RSV hospitalizations in children less than two years old as the
339 RSV indicator may not fully reflect viral activity in adults. However, the pattern in
340 adults is similar to that observed in children, and for the model performance, the
341 most important factor is the fluctuation over time rather than the absolute
342 numbers. Third, although the SHI database is representative of the German
343 population, the age distribution is slightly skewed towards young individuals. To
344 account for this difference, we used correction factors to standardize for age in the
345 incidence calculation. Lastly, we did not limit the population denominators to those

346 individuals at risk of a specific condition (e.g., limit the denominator for the RSV-
347 attributable COPD events to those with COPD diagnosis), which would likely
348 increase the reported incidence rate.

349 In conclusion, our study showed a high and largely unrecognized cardiovascular
350 and respiratory burden of RSV among adults in Germany. Substantial
351 underestimation of RSV cases emphasizes the need for standard-of-care testing,
352 also among adults with cardiovascular symptoms. Newly introduced vaccines
353 might have a high impact, not only on respiratory hospitalization but also on
354 cardiac hospitalizations.

355

356 **Acknowledgements**

357 **Funding**

358 This study was funded by Pfizer Ltd.

359 **Medical Writing, Editorial, and Other Assistance**

360 Editorial assistance in the preparation of this article was provided by Dr. Somsuvro
361 Basu of P95. Support for this assistance was funded by Pfizer Ltd.

362 **Data availability**

363 The datasets generated and/or analyzed during this study are not publicly
364 available (data provider's restrictions). Weekly counts of hospitalized cases and
365 extrapolation factors were provided by the Gesundheitsforen Leipzig GmbH.

366

367

368 **Conflicts of interests**

369 Aleksandra Polkowska-Kramek, Robin Bruyndonckx, Worku Biyadgie Ewnetu,
370 Pimnara Peerawaranun, Maribel Casas, Thao Mai Phuong Tran are employees of
371 P95 Epidemiology & Pharmacovigilance, which received funding from Pfizer to
372 conduct the research described in this manuscript and for manuscript
373 development. Caihua Liang, Caroline Lade, Lea Johanna Bayer, Bennet Huebbe,
374 Gordon Brestrich, Christof von Eiff, Bradford D. Gessner, and Elizabeth Begier are
375 Pfizer employees and may own Pfizer stock. Gernot Rohde is an expert in the field
376 of RSV and received an honorarium from Pfizer for input on the study design.

377

378 **References**

- 379 1. Falsey AR. Respiratory syncytial virus infection in adults. *Semin Respir Crit*
380 *Care Med* 2007;28:171-81.
- 381 2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory
382 syncytial virus infection in elderly and high-risk adults. *N Engl J Med*
383 2005;352:1749-59.
- 384 3. Falsey AR. Respiratory Syncytial Virus Infection in Elderly Adults. *Drugs*
385 *Aging* 2005;22:578-87.
- 386 4. Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al.
387 Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults
388 With RSV Infection in High-Income Countries. *Open Forum Infect Dis*
389 2023;ofad513.
- 390 5. Rozenbaum MH, Begier E, Kurosky SK, Whelan J, Bem D, Pouwels KB, et al.
391 Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of
392 Current Data. *Infect Dis Ther* 2023;12:1487-504.
- 393 6. Ramirez J, Carrico R, Wilde A, Junkins A, Furmanek S, Chandler T, et al.
394 Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When
395 Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT-PCR.
396 *Infect Dis Ther* 2023;12:1593-603.
- 397 7. Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al.
398 Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to
399 Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.
400 *J Infect Dis* 2023;228:173-84.
- 401 8. Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low Levels
402 of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in
403 the United States. *Infect Dis Ther* 2023;12:677-85.
- 404 9. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of
405 Medically Attended RSV Among US Adults: A Systematic Review and Meta-
406 analysis. *Open Forum Infect Dis* 2022;9:ofac300.
- 407 10. Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et
408 al. Modelling estimates of the burden of Respiratory Syncytial virus infection in
409 adults and the elderly in the United Kingdom. *BMC Infect Dis* 2015;15:443.
- 410 11. Ambrosch A, Lubber D, Klawonn F, Kabesch M. Focusing on severe infections
411 with the respiratory syncytial virus (RSV) in adults: Risk factors, symptomatology
412 and clinical course compared to influenza A / B and the original SARS-CoV-2
413 strain. *J Clin Virol* 2023;161:105399.
- 414 12. Branche AR, Saiman L, Walsh EE, Falsey AR, Sieling WD, Greendyke W, et
415 al. Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults,
416 2017-2020. *Clin Infect Dis* 2022;74:1004-11.
- 417 13. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation
418 of using ICD-10 code data for respiratory syncytial virus surveillance. *Influenza*
419 *Other Respir Viruses* 2020;14:630-7.
- 420 14. Adeli M, El-Shareif T, Hendaus MA. Asthma exacerbation related to viral
421 infections: An up to date summary. *J Family Med Prim Care* 2019;8:2753-9.
- 422 15. Linden D, Guo-Parke H, Coyle PV, Fairley D, McAuley DF, Taggart CC, et al.
423 Respiratory viral infection: a potential "missing link" in the pathogenesis of COPD.
424 *Eur Respir Rev* 2019;28.
- 425 16. Rohde G, Wiethage A, Borg I, Kauth M, Bauer TT, Gillissen A, et al.
426 Respiratory viruses in exacerbations of chronic obstructive pulmonary disease
427 requiring hospitalisation: a case-control study. *Thorax* 2003;58:37-42.

- 428 17. Ramaswamy M, Groskreutz DJ, Look DC. Recognizing the importance of
429 respiratory syncytial virus in chronic obstructive pulmonary disease. *Copd*
430 2009;6:64-75.
- 431 18. Westerly BD, Peebles RS, Jr. Respiratory syncytial virus infections in the
432 adult asthmatic--mechanisms of host susceptibility and viral subversion. *Immunol*
433 *Allergy Clin North Am* 2010;30:523-39, vi-vii.
- 434 19. Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus
435 and Associations With Cardiovascular Disease in Adults. *J Am Coll Cardiol*
436 2018;71:1574-83.
- 437 20. Bosco E, van Aalst R, McConeghy KW, Silva J, Moyo P, Eliot MN, et al.
438 Estimated Cardiorespiratory Hospitalizations Attributable to Influenza and
439 Respiratory Syncytial Virus Among Long-term Care Facility Residents. *JAMA*
440 *network open* 2021;4:e2111806.
- 441 21. Kawashima H, Inagaki N, Nakayama T, Morichi S, Nishimata S, Yamanaka
442 G, et al. Cardiac Complications Caused by Respiratory Syncytial Virus Infection:
443 Questionnaire Survey and a Literature Review. *Glob Pediatr Health*
444 2021;8:2333794x211044114.
- 445 22. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal
446 Influenza Infections and Cardiovascular Disease Mortality. *JAMA Cardiol*
447 2016;1:274-81.
- 448 23. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial
449 virus infection--a systematic review. *Crit Care* 2006;10:R107.
- 450 24. Gkentzi D, Dimitriou G, Karatza A. Non-pulmonary manifestations of
451 respiratory syncytial virus infection. *J Thorac Dis* 2018;10:S3815-s8.
- 452 25. Franczuk P, Tkaczyszyn M, Kulak M, Domenico E, Ponikowski P, Jankowska
453 EA. Cardiovascular Complications of Viral Respiratory Infections and COVID-19.
454 *Biomedicines* 2022;11.
- 455 26. Haeberer M, Bruyndonckx R, Polkowska-Kramek A, Torres A, Liang C,
456 Nuttens C, et al. Estimated Respiratory Syncytial Virus-Related Hospitalizations
457 and Deaths Among Children and Adults in Spain, 2016-2019. *Infect Dis Ther*
458 2024.
- 459 27. Matias G, Taylor RJ, Haguinet F, Schuck-Paim C, Lustig RL, Shinde V.
460 Estimates of mortality attributable to influenza and RSV in the United States
461 during 1997-2009 by influenza type or subtype, age, cause of death, and risk
462 status. *Influenza and other respiratory viruses* 2014;8:507-15.
- 463 28. Goldstein E, Greene SK, Olson DR, Hanage WP, Lipsitch M. Estimating the
464 hospitalization burden associated with influenza and respiratory syncytial virus in
465 New York City, 2003-2011. *Influenza Other Respir Viruses* 2015;9:225-33.
- 466 29. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et
467 al. Hospitalizations associated with influenza and respiratory syncytial virus in the
468 United States, 1993-2008. *Clinical infectious diseases : an official publication of*
469 *the Infectious Diseases Society of America* 2012;54:1427-36.
- 470 30. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al.
471 Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden
472 of Older Adults in High-Income Countries: a Systematic Review and Modelling
473 Study. *Infect Dis Ther* 2023;12:1137-49.
- 474 31. Polkowska-Kramek A, Begier E, Bruyndonckx R, Liang C, Beese C, Brestrich
475 G, et al. Estimated Incidence of Hospitalizations and Deaths Attributable to
476 Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015
477 and 2019. *Infect Dis Ther* 2024.

- 478 32. Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et
479 al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. *N Engl J*
480 *Med* 2023;388:595-608.
- 481 33. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al.
482 Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. *N Engl J*
483 *Med* 2023;388:1465-77.
- 484 34. Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R).
485 [https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-](https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx)
486 [U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx](https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx).
- 487 35. GmbH GL. Deutsche Analysedatenbank für Evaluation und
488 Versorgungsforschung, Stand Januar. 2022.
489 [https://www.gesundheitsforen.net/GFL/Services/Analytik/Gesundheitsforen%20Le](https://www.gesundheitsforen.net/GFL/Services/Analytik/Gesundheitsforen%20Leipzig_DADB_Q1%202024.pdf)
490 [ipzig_DADB_Q1%202024.pdf](https://www.gesundheitsforen.net/GFL/Services/Analytik/Gesundheitsforen%20Leipzig_DADB_Q1%202024.pdf). Date last accessed: 19.04.2024 2024.
- 491 36. Oh DY, Buda S, Biere B, Reiche J, Schlosser F, Duwe S, et al. Trends in
492 respiratory virus circulation following COVID-19-targeted nonpharmaceutical
493 interventions in Germany, January - September 2020: Analysis of national
494 surveillance data. *Lancet Reg Health Eur* 2021;6:100112.
- 495 37. Zheng Z, Warren JL, Shapiro ED, Pitzer VE, Weinberger DM. Estimated
496 incidence of respiratory hospitalizations attributable to RSV infections across age
497 and socioeconomic groups. *Pneumonia (Nathan)* 2022;14:6.
- 498 38. Casiano-Colón AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR. Lack of
499 sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus
500 infection in adults. *J Clin Virol* 2003;28:169-74.
- 501 39. Calvo C, Pozo F, García-García ML, Sanchez M, Lopez-Valero M, Pérez-Breña
502 P, et al. Detection of new respiratory viruses in hospitalized infants with
503 bronchiolitis: a three-year prospective study. *Acta Paediatr* 2010;99:883-7.
- 504 40. Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S, et al.
505 Prospective multicenter study of viral etiology and hospital length of stay in
506 children with severe bronchiolitis. *Arch Pediatr Adolesc Med* 2012;166:700-6.
- 507 41. Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, Mbaga DS, Fatawou Modiyinji
508 A, Njouom R. Systematic review and meta-analysis of the prevalence of common
509 respiratory viruses in children < 2 years with bronchiolitis in the pre-COVID-19
510 pandemic era. *PLoS One* 2020;15:e0242302.
- 511 42. Bruyndonckx R, Polkowska-Kramek A, Liang C, Nuttens C, Tran TMP,
512 Gessner BD, et al. Estimation of Symptomatic Respiratory Syncytial Virus Infection
513 Incidence in Adults in Multiple Countries: A Time-Series Model-Based Analysis
514 Protocol. *Infect Dis Ther* 2024.
- 515 43. Good Epidemiological Practice. Guidelines for Proper Conduct of
516 Epidemiological Research, (2007).
- 517 44. Niekler P, Goettler D, Liese JG, Streng A. Hospitalizations due to respiratory
518 syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost
519 data analysis (2010-2019). *Infection* 2023.
- 520 45. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract
521 infections and risk of first-time acute myocardial infarction. *Lancet*
522 1998;351:1467-71.
- 523 46. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of
524 myocardial infarction and stroke after acute infection or vaccination. *N Engl J Med*
525 2004;351:2611-8.
- 526 47. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does
527 acute endothelial dysfunction provide a link? *Lancet* 1997;349:1391-2.

- 528 48. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM,
529 et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019:
530 Update From the GBD 2019 Study. *J Am Coll Cardiol* 2020;76:2982-3021.
- 531 49. Zangiabadian M, Nejadghaderi SA, Mirsaeidi M, Hajikhani B, Goudarzi M,
532 Goudarzi H, et al. Protective effect of influenza vaccination on cardiovascular
533 diseases: a systematic review and meta-analysis. *Sci Rep* 2020;10:20656.
- 534 50. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza
535 vaccination and reduction in hospitalizations for cardiac disease and stroke among
536 the elderly. *N Engl J Med* 2003;348:1322-32.
- 537 51. Hanquet G, Theilacker C, Vietri J, Sepúlveda-Pachón I, Menon S, Gessner B,
538 et al. Best Practices for Identifying Hospitalized Lower Respiratory Tract Infections
539 Using Administrative Data: A Systematic Literature Review of Validation Studies.
540 *Infect Dis Ther* 2024;13:921-40.
- 541 52. Wiseman DJ, Thwaites RS, Ritchie AI, Finney L, Macleod M, Kamal F, et al.
542 RSV-related Community COPD Exacerbations and Novel Diagnostics: A Binational
543 Prospective Cohort Study. *Am J Respir Crit Care Med* 2024.
- 544 53. Colosia AD, Yang J, Hillson E, Mauskopf J, Copley-Merriman C, Shinde V, et
545 al. The epidemiology of medically attended respiratory syncytial virus in older
546 adults in the United States: A systematic review. *PLoS One* 2017;12:e0182321.
- 547 54. Agarwal D. COPD generates substantial cost for health systems. *Lancet Glob*
548 *Health* 2023;11:e1138-e9.
- 549 55. Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, et al. The global
550 economic burden of chronic obstructive pulmonary disease for 204 countries and
551 territories in 2020-50: a health-augmented macroeconomic modelling study.
552 *Lancet Glob Health* 2023;11:e1183-e93.
- 553 56. Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of
554 Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the
555 Advisory Committee on Immunization Practices - United States, 2023. *MMWR*
556 *Morb Mortal Wkly Rep* 2023;72:793-801.
- 557
- 558
- 559
- 560
- 561
- 562
- 563
- 564
- 565
- 566
- 567

Tables

Table 1 Estimated incidence rate per 100,000 person-years of RSV-attributable respiratory hospitalizations and percentage (%) of all respective respiratory hospitalizations attributable to RSV infections in adults in Germany, 2015-2019

Age groups	2015		2016		2017		2018		2019	
	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%
Influenza/pneumonia										
18-44	2.7 [0, 6.0]	2.9	4.2 [0, 9.1]	3.6	4.8 [0, 10.4]	4.4	3.8 [0, 8.4]	3.1	5.0 [0, 11.0]	4.6
45-59	3.3 [0, 8.1]	1.3	4.8 [0, 11.8]	1.8	5.2 [0, 13.0]	1.9	4.1 [0, 10.3]	1.4	5.5 [0, 13.6]	2.0
60-74	20.4 [0, 42.6]	1.9	20.8 [0, 43.6]	1.8	27.7 [0, 57.9]	2.4	18.1 [0, 37.9]	1.6	23.9 [0, 50.0]	2.2
≥75	231.3 [137.4, 330.0]	4.3	253.7 [150.7, 362.0]	4.5	292.4 [173.7, 417.2]	5.1	205.8 [122.3, 293.7]	3.6	273.9 [162.7, 390.8]	5.0
≥60*	73.7	3.4	81.0	3.5	97.9	4.1	67	2.8	88.4	3.9
Bronchitis/bronchiolitis										
18-44	0.4 [0, 2.7]	0.9	0.5 [0, 3.3]	1.0	0.6 [0, 4.5]	1.4	0.4 [0, 3.2]	0.9	0.6 [0, 4.3]	1.5
45-59	6.6 [3.4, 10.1]	8.6	7.7 [4.0, 11.9]	9.2	10.0 [5.2, 15.4]	11.0	6.9 [3.6, 10.7]	7.8	9.7 [5.0, 14.9]	11.1
60-74	25.5 [14.9, 35.8]	9.0	24.1 [14.1, 33.9]	8.8	34.4 [20.1, 48.4]	11.8	21.2 [12.4, 29.8]	7.3	28.5 [16.7, 40.1]	10.9
≥75	283.6 [222.9, 343.8]	19.6	281.9 [221.6, 341.8]	20.1	359.8 [282.8, 436.3]	22.4	234.4 [184.2, 284.2]	16.6	314.2 [247.0, 381.0]	24.5
≥60*	91.3	15.5	91.5	15.9	121.8	18.7	77.2	13.1	102.9	19.3
Chronic lower respiratory tract diseases										
18-44	NA		NA		NA		NA		NA	
45-59	18.9 [1.7, 35.5]	2.4	17.4 [1.5, 32.7]	2.0	28.1 [2.5, 52.8]	3.1	17.5 [1.6, 32.9]	2.0	25.4 [2.3, 47.8]	2.9
60-74	74.4 [17.2, 133.8]	2.4	70.4 [16.3, 126.6]	2.1	100.5 [23.2, 180.7]	3.0	61.8 [14.3, 111.2]	1.9	83.3 [19.2, 149.8]	2.6
≥75	279.5 [125.7, 432.5]	3.3	239.0 [107.5, 369.8]	2.6	342.7 [154.1, 530.3]	3.9	211.4 [95.1, 327.1]	2.6	293.0 [131.7, 453.3]	3.6
≥60*	128.9	2.8	116.7	2.3	168.2	3.4	102.9	2.2	140.1	3.1
Upper respiratory tract diseases										
18-44	10.9 [0, 27.3]	1.7	10.4 [0, 26.1]	1.5	17.4 [0, 43.7]	2.4	11.1 [0, 27.8]	1.6	15.8 [0, 39.7]	2.3

Age groups	2015		2016		2017		2018		2019	
	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%
45-59	8.2 [0, 21.7]	1.9	8.1 [0, 21.3]	1.7	12.4 [0, 32.9]	2.5	8.0 [0, 21.1]	1.7	11.4 [0, 30.1]	2.4
60-74	18.6 [0.4, 35.5]	3.6	17.6 [0.4, 33.6]	3.1	25.1 [0.6, 48.0]	4.4	15.4 [0.4, 29.5]	2.8	20.8 [0.5, 39.8]	3.9
≥75	55.9 [25.7, 86.4]	7.2	51.2 [23.5, 79.1]	6.4	70.0 [32.2, 108.2]	8.4	44.5 [20.4, 68.7]	5.5	60.6 [27.8, 93.5]	8.1
≥60*	28.7	4.8	26.9	4.1	37.9	5.8	23.5	3.7	31.7	5.2

CI: confidence interval; IR: incidence rate extrapolated to the national level; NA: not applicable due to data not suitable for modeling

** Based on pooling results for models fitted to adults for included age groups, thus confidence intervals are not provided.*

Table 2 Estimated incidence rate per 100,000 person-years of RSV-attributable cardiovascular hospitalizations and percentage (%) of all respective cardiovascular hospitalizations attributable to RSV infections in adults in Germany, 2015-2019

Age groups	2015		2016		2017		2018		2019	
	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%
Chronic heart failure exacerbation										
18-44	NA		NA		NA		NA		NA	
45-59	NA		NA		NA		NA		NA	
60-74	65.9 [14.3, 117.0]	2.3	58.2 [12.6, 103.4]	1.9	87.1 [18.9, 154.6]	2.8	52.1 [11.3, 92.4]	1.8	71.4 [15.5, 126.7]	2.4
≥75	302.5 [76.6, 542.1]	1.9	300.7 [76.2, 538.8]	1.8	383.8 [97.2, 687.8]	2.3	250.0 [63.3, 448.1]	1.5	335.1 [84.9, 600.6]	2.1
≥60*	127.9	2.0	123.0	1.8	168.7	2.5	105.3	1.6	141.7	2.2
Ischemic heart diseases										
18-44	NA		NA		NA		NA		NA	
45-59	15.4 [0, 34.0]	1.6	15.2 [0, 33.5]	1.5	23.3 [0, 51.5]	2.2	15.0 [0, 33.1]	1.5	21.4 [0, 47.2]	2.1
60-74	92.1 [0.6, 175.4]	1.8	87.2 [0.6, 166.0]	1.6	124.4 [0.8, 236.8]	2.5	76.5 [0.5, 145.7]	1.6	103.1 [0.7, 196.3]	2.1
≥75	357.9 [47.9, 672.1]	1.9	327.7 [43.9, 615.5]	1.6	448.2 [60.0, 841.8]	2.3	284.5 [38.1, 534.4]	1.5	387.5 [51.9, 727.9]	2.1
≥60*	162.5	2.0	152.6	1.8	214.5	2.5	133.3	1.6	179.8	2.2
Arrhythmia										
18-44	NA		NA		NA		NA		NA	
45-59	16.3 [1.8, 31.8]	2.5	15.0 [1.7, 29.2]	2.0	24.2 [2.7, 47.2]	3.1	15.1 [1.7, 29.5]	2.0	22.0 [2.5, 42.8]	2.9
60-74	108.7 [26.5, 175.8]	2.6	96.1 [23.5, 155.4]	2.2	143.7 [35.1, 232.4]	3.3	85.9 [21.0, 138.9]	2.1	117.8 [28.7, 190.5]	2.8
≥75	460.9 [118.3, 786.7]	2.1	394.2 [101.1, 672.8]	1.6	565.2 [145.0, 964.6]	2.4	348.6 [89.5, 595.0]	1.5	483.1 [124.0, 824.5]	2.0
≥60*	201.5	2.3	176.6	1.8	260.4	2.7	157.2	1.7	215.8	2.3
Cerebrovascular diseases										
18-44	NA		NA		NA		NA		NA	
45-59	NA		NA		NA		NA		NA	
60-74	NA		NA		NA		NA		NA	
≥75	97.6 [9.9, 189.7]	1.7	83.5 [8.5, 162.2]	1.4	119.7 [12.1, 232.6]	2.0	73.9 [7.5, 143.5]	1.3	102.3 [10.4, 198.8]	1.9

CI: confidence interval; IR: incidence rate extrapolated to the national level; NA: not applicable due to data not suitable for modeling

* Based on pooling results for models fitted to adults for included age groups, thus confidence intervals are not provided.